PTC Therapeutics (PTCT) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does PTC Therapeutics (PTCT) do?
PTC Therapeutics Inc (PTCT) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells prescription medicines for rare genetic conditions such as Duchenne muscular dystrophy. Develops small-molecule medicines and gene therapies engineered to treat rare genetic and neurological disorders. It is worth $4.87B on the market and sold $1.15B over the last year.
- Market cap
- $4.87B
- P/E ratio
- None (reported a loss)
- Annual sales
- $1.15B
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 18, 2026
Brands and businesses behind PTCT
- Translarna: Treats nonsense mutation Duchenne muscular dystrophy through direct sales to healthcare providers internationally.
- Upstaza: Treats AADC deficiency by selling single-dose surgical gene therapy treatments to specialized medical centers.
PTCT’s flags, in plain English
Each flag is a number from PTC Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Wide Gross Margin
Gross margin of 89.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Still Climbing
Sales up 35.4% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Stupid Cash
Can pay this year's bills 3.3 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Burning Cash
Losing money, profit margin of -9.2%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
Questions about PTCT
How big is PTC Therapeutics?
PTC Therapeutics’ market cap is $4.87B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.15B: what customers paid the company over the last year, before any costs.
What is PTCT’s P/E ratio?
PTCT has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with PTCT?
European regulators have recommended against renewing marketing authorization for Translarna, putting significant international revenue at risk. That is one risk on PTC Therapeutics’ card. Its first risk flag is Burning Cash, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From PTC Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PTCT’s filings on SEC.gov. The Margin Monkey is research, not advice.
